Publication date: Available online 20 November 2026 Source: Blood Neoplasia Author(s): John Preston Claiborne, Venkata Preetam Sandeep Kaduluri, Hua-Ling Tsai, Gabriel Ghiaur, Ivana Gojo, Amy E. DeZern, B. Douglas Smith, Tania Jain, Gabrielle T. Prince, Javier Bolaños-Meade, Ephraim Fuchs, Philip H. Imus, Lukasz P. Gondek, William Brian Dalton, Theodoros Karantanos, Ravi Varadhan, Mark J. Levis, Richard J. Jones, Jonathan A. Webster, Alexander J. Ambinder
Post-transplant outcomes after intensive chemotherapy versus hypomethylating agent/venetoclax in acute myeloid leukemia. // Blood Neoplasia. – URL: https://www.sciencedirect.com/science/article/pii/S2950328026001500?dgcid=rss_sd_all
Post-transplant outcomes after intensive chemotherapy versus hypomethylating agent/venetoclax in acute myeloid leukemia. Blood Neoplasia. https://www.sciencedirect.com/science/article/pii/S2950328026001500?dgcid=rss_sd_all
“Post-transplant outcomes after intensive chemotherapy versus hypomethylating agent/venetoclax in acute myeloid leukemia.” Blood Neoplasia.
@article{article118398,
title = {Post-transplant outcomes after intensive chemotherapy versus hypomethylating agent/venetoclax in acute myeloid leukemia},
journal = {Blood Neoplasia},
url = {https://www.sciencedirect.com/science/article/pii/S2950328026001500?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment